var data={"title":"Ampullary adenomas: Management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Ampullary adenomas: Management</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/contributors\" class=\"contributor contributor_credentials\">John A Martin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/contributors\" class=\"contributor contributor_credentials\">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adenomas are the most common benign lesions of the ampulla but have the potential to undergo malignant transformation to ampullary carcinomas [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/1-10\" class=\"abstract_t\">1-10</a>]. Approximately 15 to 60 percent of ampullary adenomas harbor small foci of adenocarcinoma [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/7,11-15\" class=\"abstract_t\">7,11-15</a>]. Ampullary adenomas can occur sporadically or in the setting of an adenomatous polyposis syndrome (eg, familial adenomatous polyposis and <em>MUTYH</em>-associated polyposis). This topic reviews the management of ampullary adenomas. The clinical manifestations and diagnosis of ampullary adenomas and the management of ampullary carcinoma are discussed separately. (See <a href=\"topic.htm?path=ampullary-adenomas-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Ampullary adenomas: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=ampullary-carcinoma-epidemiology-clinical-manifestations-diagnosis-and-staging\" class=\"medical medical_review\">&quot;Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2467149757\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H654731067\"><span class=\"h2\">General approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the absence of randomized trials comparing different treatment strategies, recommendations for the management of ampullary adenomas are based on observational studies and clinical experience. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sporadic ampullary adenoma</strong> &ndash; We excise all sporadic ampullary adenomas. Excision is particularly important in patients with adenomas that are causing symptoms or that have foci of high-grade dysplasia. In patients who do not undergo excision, we perform surveillance duodenoscopy (upper endoscopy using a side-viewing endoscope) every 6 to 12 months, performing multiple cold-forceps biopsies of the papilla of Vater. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adenomatous polyposis syndrome</strong> &ndash; We also resect ampullary adenomas in patients with an adenomatous polyposis syndrome. The choice and timing of excision in patients with a familial polyposis syndrome should be individualized based on the patient's age and the number of concurrent duodenal adenomas, and is discussed in detail separately. (See <a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families#H3263544255\" class=\"medical medical_review\">&quot;Familial adenomatous polyposis: Screening and management of patients and families&quot;, section on 'Duodenal polyps'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4224614498\"><span class=\"h2\">Selection of a treatment modality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice of treatment modality depends on the characteristics of the adenoma, the presence of concurrent duodenal polyposis, the presence of endoscopic expertise, and the willingness of the patient to undergo long-term endoscopic surveillance following endoscopic papillectomy or surgical ampullectomy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/16\" class=\"abstract_t\">16</a>]. The role of endoscopy in ampullary adenomas was reviewed in a <a href=\"http://www.asge.org/assets/0/71542/71544/8f8a3952917f4fe78f3855ff0ec77d07.pdf&amp;token=qowHMDqM17VFgbc2uhya8i0A+TBXQMI2+ipAvBP9e3MlHkUcwJRjimZww6uwurVGT9vn4FSv/nFNRzrOS9CX0UZYvsAY1nQBSP8dAhkCSwM=&amp;TOPIC_ID=649\" target=\"_blank\" class=\"external\">guideline statement</a> published by the American Society for Gastrointestinal Endoscopy in 2006 [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/16\" class=\"abstract_t\">16</a>]. The following discussion is largely consistent with the guideline recommendations. (See <a href=\"#H1761862354\" class=\"local\">'Post-treatment follow-up'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We perform endoscopic ampullectomy in patients with ampullary adenomas with all of the following characteristics:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Less than 2 to 3 cm in size &ndash; While there are no universally accepted criteria for the maximum size of adenoma amenable to endoscopic excision, we typically limit endoscopic snare papillectomy to lesions less than 2 to 3 cm in size. While some experts have suggested that endoscopic excision may be reasonable for sporadic adenomas less than 4 to 4.5 cm in largest dimension with no evidence of intraductal growth or malignancy, studies have demonstrated adenocarcinomas can be present within smaller polyps [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/11,17-20\" class=\"abstract_t\">11,17-20</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Less than 1 cm ingrowth into the bile or pancreatic duct.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Absence of advanced duodenal polyposis (Modified Spiegelman stage IV) (<a href=\"image.htm?imageKey=GAST%2F71691\" class=\"graphic graphic_table graphicRef71691 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest surgical management in patients with any one the following characteristics: </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Adenoma too large to be excised endoscopically (&gt;2 to 3 cm)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Significant (&ge;1 cm) ingrowth of the adenoma into the bile or pancreatic duct</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Advanced duodenal polyposis (Modified Spiegelman stage IV)</p><p/><p class=\"bulletIndent1\">For patients undergoing surgical excision, we suggest pancreaticoduodenectomy rather than surgical ampullectomy. Surgical ampullectomy may have lower morbidity and perioperative mortality rates as compared with pancreaticoduodenectomy but requires endoscopic surveillance due to the risk of adenoma recurrence. (See <a href=\"#H699284250\" class=\"local\">'Endoscopic surveillance'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We reserve endoscopic drainage for patients with symptomatic ampullary obstruction who are unable or unwilling to undergo endoscopic papillectomy or surgery. (See <a href=\"#H2206746571\" class=\"local\">'Endoscopic palliation'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Endoscopic papillectomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endoscopic papillectomy involves resection of tissue from the papilla and requires expertise in interventional endoscopy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/21-24\" class=\"abstract_t\">21-24</a>]. </p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Endoscopic resection technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goal of endoscopic excision is to achieve complete removal of the ampullary neoplasm [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/17,25,26\" class=\"abstract_t\">17,25,26</a>]. En bloc excision is the preferred method since it increases the likelihood of complete removal, especially if the adenoma is abutting the biliary and pancreatic orifices. In addition, en bloc excision provides a pathologic specimen with margins that can be assessed in the event carcinoma is detected. En bloc excision using the standard snare technique may not be technically feasible in the presence of one or more of the following: large adenoma size, limited endoscopic accessibility, or sessile nature of the adenoma, including laterally-spreading extra-papillary extension. In these cases, piecemeal excision may be undertaken with adjuvant ablative therapy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"#H3181296039\" class=\"local\">'Adjunctive techniques'</a> below.)</p><p>Endoscopic papillectomy is typically performed with the standard monopolar diathermic snare used in colonoscopic polypectomy. The snare should be relatively soft and flexible to allow manipulation across the elevator of a duodenoscope. We routinely groom the snare to create a gentle curve at the tip. This facilitates passage of the snare through the right-angle turn in the accessory channel of the duodenoscope and across the elevator. We use the larger channel therapeutic duodenoscope to allow easier passage of both the snare and thermal ablation probes. The larger channel also permits aspiration of insufflated air and argon gas when a snare or probe is present in the channel. In patients with an intraductally extending adenoma we use a balloon-tipped catheter to improve exposure and allow for more complete endoscopic excision [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/28\" class=\"abstract_t\">28</a>]. </p><p>The excised specimen can migrate distally in the duodenum and should be retrieved immediately after excision. The tissue should be retrieved with a snare or a retrieval net so that the margins can be clearly assessed. Aspiration through the accessory channel of the duodenoscope into a trap can fragment the specimen and should be avoided.</p><p class=\"headingAnchor\" id=\"H3181296039\"><span class=\"h3\">Adjunctive techniques</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adjunctive techniques have been used to increase the technical success and decrease the incidence of complications. (See <a href=\"#H20\" class=\"local\">'Complications'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sphincterotomy</strong> <strong>and</strong> <strong>stent</strong> <strong>placement</strong> &ndash; A biliary sphincterotomy can facilitate complete excision of the adenomatous tissue if it is situated partly in the biliary orifice. A pancreatic or biliary sphincterotomy can also facilitate placement of a stent. Prophylactic placement of a pancreatic duct stent decreases the risk of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis following ampullectomy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/17,18,29-33\" class=\"abstract_t\">17,18,29-33</a>]. (See <a href=\"topic.htm?path=prophylactic-pancreatic-stents-to-prevent-ercp-induced-pancreatitis-when-do-you-use-them\" class=\"medical medical_review\">&quot;Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?&quot;</a>.) </p><p/><p class=\"bulletIndent1\">If the size or irregularity of the adenoma margins favors piecemeal removal, placement of a pancreatic stent prior to the excision may protect the orifice from thermal injury from the snare. However, with an en bloc excision, the stent cannot be placed beforehand, because the snare encircles the ampulla from which the stent would be protruding (such that, in order to remove the ampulla, the stent would have to be transected). However, stent placement following papillectomy can be technically challenging. Pre-resection stenting with an insulated pancreatic stent, with retrieval of the specimen via perpendicular needle-knife incision of the snared ampullary neoplasm has been described, but is not widely performed [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/34\" class=\"abstract_t\">34</a>]. </p><p/><p class=\"bulletIndent1\">The pancreatic stent is generally removed two or three weeks later, at which time any suspicious-appearing residual polypoid tissue can be removed to ensure complete excision.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Ablation</strong> <strong>of</strong> <strong>residual</strong> <strong>tissue</strong> &ndash; In patients with residual tissue around the biliary and pancreatic duct orifices, fulguration (thermal ablation) is necessary to decrease the risk of adenoma recurrence. We employ argon plasma coagulation (APC) to ablate residual tissue and typically use a 7 Fr probe at a setting of 50 to 60 watts, paying careful attention to avoid aggressive tissue destruction around the orifices [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/18,31\" class=\"abstract_t\">18,31</a>]. We perform a biliary sphincterotomy prior to fulguration to lay open the lower end of the bile duct, and place a pancreatic stent before thermally coagulating around the pancreatic orifice. Fulguration of residual tissue can also be performed with monopolar coagulation, bipolar coagulation, Nd:YAG laser, or photodynamic therapy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/21-23,31,35\" class=\"abstract_t\">21-23,31,35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Submucosal</strong> <strong>saline</strong> <strong>injection</strong> &ndash; Submucosal injection of saline prior to papillectomy is controversial. While local saline injection prevents a deeper burn into the duodenal wall, it is associated with significant disadvantages that have limited its use [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/18,31\" class=\"abstract_t\">18,31</a>]. As the center of the ampullary lesion is tethered down by the biliary and pancreatic ducts, it may not lift with saline injection. In addition, the surrounding normal mucosa, which does lift, may &quot;mushroom&quot; around the adenoma and partially bury its central aspect, preventing adequate snare placement and compromising complete excision. (See <a href=\"topic.htm?path=endoscopic-removal-of-large-colon-polyps#H59653701\" class=\"medical medical_review\">&quot;Endoscopic removal of large colon polyps&quot;, section on 'Submucosal injection'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2280065766\"><span class=\"h3\">Prophylaxis for post-ERCP pancreatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients undergoing papillectomy are at increased risk for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. In addition to pancreatic stent placement, we administer rectal <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> immediately after endoscopic papillectomy to decrease the incidence of post-ERCP pancreatitis. (See <a href=\"#H20\" class=\"local\">'Complications'</a> below and <a href=\"topic.htm?path=post-endoscopic-retrograde-cholangiopancreatography-ercp-pancreatitis#H13\" class=\"medical medical_review\">&quot;Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis&quot;, section on 'Chemoprevention'</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 15 percent of patients develop complications after endoscopic papillectomy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/6,17-19,21,23,25,33,36-42\" class=\"abstract_t\">6,17-19,21,23,25,33,36-42</a>]. Early complications include acute pancreatitis (8 to 15 percent), bleeding (2 to 13 percent), perforation (0 to 4 percent), and cholangitis (0 to 2 percent). Papillary stenosis is a late complication that has been reported in up to 8 percent of patients, and can develop within 7 days to 24 months after endoscopic papillectomy. While some observational studies have reported lower complication rates with endoscopic papillectomy as compared with pancreaticoduodenectomy, it is unclear if they are attributable to publication bias [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H1502852818\"><span class=\"h2\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical options for resecting ampullary adenomas include pancreaticoduodenectomy and surgical ampullectomy. </p><p class=\"headingAnchor\" id=\"H85432811\"><span class=\"h3\">Pancreaticoduodenectomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pancreaticoduodenectomy is the definitive approach for achieving curative excision of ampullary adenomas. A major advantage compared with less aggressive approaches is that it eliminates the risk of local recurrence in patients who do not have an adenomatous polyposis syndrome and do not harbor occult adenocarcinoma [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/44-46\" class=\"abstract_t\">44-46</a>]. It also eliminates the need for surveillance endoscopy in patients with sporadic adenomas.</p><p>The major disadvantages of this approach are largely related to the high postoperative morbidity and mortality rates. Data from multiple series of pancreaticoduodenectomy performed for benign and malignant ampullary tumors demonstrated an operative mortality rate of 0 to 10 percent and operative morbidity of 25 to 65 percent [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/22,44-56\" class=\"abstract_t\">22,44-56</a>]. Perioperative mortality rates are lowest (less than 4 percent) in centers with a high procedure volume. (See <a href=\"topic.htm?path=surgical-resection-of-lesions-of-the-head-of-the-pancreas#H176949700\" class=\"medical medical_review\">&quot;Surgical resection of lesions of the head of the pancreas&quot;, section on 'Perioperative morbidity and mortality'</a> and <a href=\"topic.htm?path=overview-of-surgery-in-the-treatment-of-exocrine-pancreatic-cancer-and-prognosis#H436301891\" class=\"medical medical_review\">&quot;Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis&quot;, section on 'Pancreaticoduodenectomy'</a>.)</p><p class=\"headingAnchor\" id=\"H4204106490\"><span class=\"h3\">Surgical ampullectomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ampullectomy involves removal of the entire ampulla of Vater. Surgical ampullectomy entails mobilization of the duodenum and longitudinal duodenotomy, followed either by simple excision of the ampullary neoplasm or an extended excision, involving the ampulla and adjacent duodenal and ductal tissue. The latter approach typically requires operative reconstruction of the biliary and pancreatic ducts using a sphincteroplasty technique [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/57-61\" class=\"abstract_t\">57-61</a>]. </p><p>Complications of surgical ampullectomy include gastric outlet obstruction, pancreatitis, cholangitis, and common bile duct stricture formation [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/12\" class=\"abstract_t\">12</a>]. Small observational studies suggest that surgical ampullectomy is associated with lower morbidity and perioperative mortality rates as compared with pancreaticoduodenectomy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/12,44-46,50\" class=\"abstract_t\">12,44-46,50</a>]. However, these studies are at risk for selection bias because patients with smaller neoplasms may have been more likely to undergo local excision. However, the potentially lower morbidity and perioperative mortality with surgical ampullectomy must be balanced against a higher recurrence rate and the potential for inadequate excisional margins, which may be a particular problem if an occult carcinoma is found in the resected specimen.</p><p class=\"headingAnchor\" id=\"H2206746571\"><span class=\"h2\">Endoscopic palliation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endoscopic drainage of ductal obstruction in ampullary tumors via papillotomy or transpapillary stent placement provides effective symptomatic relief in patients with obstruction of the biliary or pancreatic ducts [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/62-68\" class=\"abstract_t\">62-68</a>]. Obstruction extending proximal to the papilla may require placement of a biliary or pancreatic stent, with or without concomitant sphincterotomy. Common bile duct stones, sometimes encountered in association with ampullary adenomas, can be removed with a Dormia basket or extraction balloon catheter following sphincterotomy. </p><p>Biliary radiofrequency catheter ablation during ERCP has been used for primary management of ampullary adenoma in patients who were not candidates for surgical or endoscopic excision [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/69,70\" class=\"abstract_t\">69,70</a>]. (See <a href=\"topic.htm?path=endoscopic-management-of-bile-duct-stones-standard-techniques-and-mechanical-lithotripsy\" class=\"medical medical_review\">&quot;Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1761862354\"><span class=\"h1\">POST-TREATMENT FOLLOW-UP</span></p><p class=\"headingAnchor\" id=\"H3112295874\"><span class=\"h2\">Incomplete resection and adenoma recurrence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary success rates for endoscopic papillectomy range from 46 to 92 percent, with recurrence rates of up to 33 percent [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/25,26\" class=\"abstract_t\">25,26</a>]. The risk of adenoma recurrence is higher with increasing adenoma size, the presence of genetic predisposition to adenoma formation (eg, familial adenomatous polyposis, <em>MUTYH</em>-associated polyposis), and intraductal adenoma growth [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/31,71\" class=\"abstract_t\">31,71</a>]. Pancreaticoduodenectomy eliminates the risk of adenoma recurrence in patients without an adenomatous polyposis syndrome. However, recurrence rates after surgical ampullectomy range from 5 to 50 percent [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/5,8,12,13,44,45,57,58,72\" class=\"abstract_t\">5,8,12,13,44,45,57,58,72</a>]. In a 2016 meta-analysis of five retrospective studies that included 466 patients, surgical treatment of ampullary adenomas was associated with a higher primary success rate and lower recurrence rates as compared with endoscopic papillectomy [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/43\" class=\"abstract_t\">43</a>]. However, the meta-analysis was limited by significant heterogeneity.</p><p>Adenoma recurrence can often be managed endoscopically. However, surgery may be needed in patients with large adenomas or advanced duodenal polyposis. (See <a href=\"#H4224614498\" class=\"local\">'Selection of a treatment modality'</a> above.) </p><p class=\"headingAnchor\" id=\"H699284250\"><span class=\"h2\">Endoscopic surveillance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The frequency of endoscopic surveillance depends on the presence of an adenomatous polyposis syndrome, the treatment modality, and the characteristics of the ampullary adenoma [<a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/16\" class=\"abstract_t\">16</a>]. </p><p class=\"headingAnchor\" id=\"H4267789326\"><span class=\"h3\">Sporadic adenoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with sporadic adenomas who have undergone endoscopic papillectomy or surgical ampullectomy require endoscopic surveillance for recurrence.</p><p class=\"headingAnchor\" id=\"H12348341\"><span class=\"h4\">Initial surveillance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The frequency of endoscopic surveillance varies by adenoma size and the degree of dysplasia. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with a large polyp (&ge;2 cm) or high grade dysplasia, we perform a duodenoscopy in one to three months. In the absence of recurrence, we repeat examinations with a duodenoscope every six months for two years. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with ampullary adenomas (&lt;2 cm) and no high-grade dysplasia, we perform a duodenoscopy six months following excision. In the absence of adenoma recurrence, we perform duodenoscopy every 12 months for two years.</p><p/><p class=\"headingAnchor\" id=\"H1490828151\"><span class=\"h4\">Subsequent surveillance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with sporadic adenomas, we continue to perform duodenoscopy every three years in patients with a large polyp (&ge;2 cm) or high-grade dysplasia and every five years in patients with smaller polyps without high-grade dysplasia.</p><p class=\"headingAnchor\" id=\"H2668659724\"><span class=\"h3\">Adenomatous polyposis syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with an adenomatous polyposis syndrome (eg, familial adenomatous polyposis and <em>MUTYH</em>-associated polyposis), surveillance is required both for recurrent adenoma and for concurrent duodenum adenomas. The frequency of surveillance must be individualized based on the characteristics of the ampullary adenoma and the Modified Spigelman stage of duodenal polyposis and is discussed in detail elsewhere. (See <a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families#H3263544255\" class=\"medical medical_review\">&quot;Familial adenomatous polyposis: Screening and management of patients and families&quot;, section on 'Duodenal polyps'</a>.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adenomas are the most common benign lesions of the ampulla but have the potential to undergo malignant transformation to ampullary carcinomas. Approximately 15 to 60 percent of ampullary adenomas harbor small foci of adenocarcinoma. Ampullary adenomas can occur sporadically or in the setting of an adenomatous polyposis syndromes (eg, familial adenomatous polyposis and <em>MUTYH</em>-associated polyposis). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the absence of randomized trials comparing different treatment strategies, recommendations are based on observational studies and clinical experience. (See <a href=\"#H654731067\" class=\"local\">'General approach'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We excise all sporadic ampullary adenomas. Excision is particularly important in patients with adenomas that are causing symptoms or that have foci of high-grade dysplasia. In patients who do not undergo excision, we perform surveillance duodenoscopy (upper endoscopy using a side-viewing endoscope) every 6 to 12 months, performing multiple cold-forceps biopsies of the papilla of Vater. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We also resect ampullary adenomas in patients with an adenomatous polyposis syndrome (eg, familial adenomatous polyposis or <em>MUTYH</em>-associated polyposis). The choice and timing of excision in patients with an adenomatous polyposis syndrome should be individualized based on the patient's age and the number of concurrent duodenal adenomas.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The choice of treatment modality depends on the characteristics of the adenoma, the presence of concurrent duodenal polyposis, presence of endoscopic expertise, and willingness of the patient to undergo long-term endoscopic surveillance following endoscopic papillectomy or surgical ampullectomy. (See <a href=\"#H4224614498\" class=\"local\">'Selection of a treatment modality'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pancreaticoduodenectomy achieves curative excision of ampullary adenomas and eliminates the risk of local recurrence in patients who do not have an adenomatous polyposis syndrome and do not harbor occult adenocarcinoma. Surgical ampullectomy involves removal of the entire ampulla of Vater. Surgical ampullectomy has a potentially lower morbidity and perioperative mortality as compared with pancreaticoduodenectomy but may result in inadequate excisional margins and adenoma recurrence. (See <a href=\"#H1502852818\" class=\"local\">'Surgery'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endoscopic papillectomy involves resection of tissue from the papilla and requires expertise in interventional endoscopy. Primary success rates for endoscopic papillectomy range from 46 to 92 percent, with recurrence rates of up to 33 percent. The risk of adenoma recurrence is higher with increasing adenoma size, the presence of genetic predisposition to adenoma formation, and intraductal adenoma growth. (See <a href=\"#H11\" class=\"local\">'Endoscopic papillectomy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For most patients without evidence of malignancy within the adenoma on imaging or endoscopy, we suggest endoscopic papillectomy for ampullary adenomas rather than surgical excision, provided the patient has access to an interventional endoscopist experienced in ampullectomy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Exceptions are patients with evidence of significant (&gt;1 cm) intraductal tumor growth, patients with adenomas larger than 2 to 3 cm, or patients who prefer to undergo a definitive surgical procedure, in whom surgical excision is appropriate. We reserve endoscopic drainage for patients with symptomatic ampullary obstruction who are unable or unwilling to undergo endoscopic papillectomy or surgery. (See <a href=\"#H4224614498\" class=\"local\">'Selection of a treatment modality'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients undergoing endoscopic ampullectomy, we recommend prophylactic stenting of the pancreatic duct (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). In addition, we administer rectal <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> immediately post-endoscopic retrograde cholangiopancreatography (ERCP) after endoscopic ampullectomy. (See <a href=\"#H11\" class=\"local\">'Endoscopic papillectomy'</a> above and <a href=\"#H2280065766\" class=\"local\">'Prophylaxis for post-ERCP pancreatitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endoscopic surveillance is required following surgical ampullectomy or endoscopic ampullectomy due to the risk of adenoma recurrence with these procedures. The frequency of endoscopic surveillance depends on the presence of an adenomatous polyposis syndrome, the treatment modality, and the characteristics of the ampullary adenoma. (See <a href=\"#H699284250\" class=\"local\">'Endoscopic surveillance'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H3306332381\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The UpToDate editorial staff would like to thank Dr. Gregory B. Haber, MD, for his past contributions as an author to prior versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/1\" class=\"nounderline abstract_t\">Park SH, Kim YI, Park YH, et al. Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of the ampulla of Vater. World J Surg 2000; 24:54.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/2\" class=\"nounderline abstract_t\">Sato T, Konishi K, Kimura H, et al. Adenoma and tiny carcinoma in adenoma of the papilla of Vater--p53 and PCNA. Hepatogastroenterology 1999; 46:1959.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/3\" class=\"nounderline abstract_t\">Sellner FJ, Riegler FM, Machacek E. Implications of histological grade of tumour for the prognosis of radically resected periampullary adenocarcinoma. Eur J Surg 1999; 165:865.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/4\" class=\"nounderline abstract_t\">Stolte M, Pscherer C. Adenoma-carcinoma sequence in the papilla of Vater. Scand J Gastroenterol 1996; 31:376.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/5\" class=\"nounderline abstract_t\">Asbun HJ, Rossi RL, Munson JL. Local resection for ampullary tumors. Is there a place for it? Arch Surg 1993; 128:515.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/6\" class=\"nounderline abstract_t\">Seifert E, Schulte F, Stolte M. Adenoma and carcinoma of the duodenum and papilla of Vater: a clinicopathologic study. Am J Gastroenterol 1992; 87:37.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/7\" class=\"nounderline abstract_t\">Yamaguchi K, Enjoji M. Adenoma of the ampulla of Vater: putative precancerous lesion. Gut 1991; 32:1558.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/8\" class=\"nounderline abstract_t\">Ryan DP, Schapiro RH, Warshaw AL. Villous tumors of the duodenum. Ann Surg 1986; 203:301.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/9\" class=\"nounderline abstract_t\">Kozuka S, Tsubone M, Yamaguchi A, Hachisuka K. Adenomatous residue in cancerous papilla of Vater. Gut 1981; 22:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/10\" class=\"nounderline abstract_t\">Perzin KH, Bridge MF. Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. Cancer 1981; 48:799.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/11\" class=\"nounderline abstract_t\">Kim JH, Kim JH, Han JH, et al. Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia? Ann Surg Oncol 2009; 16:2547.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/12\" class=\"nounderline abstract_t\">Clary BM, Tyler DS, Dematos P, et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery 2000; 127:628.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/13\" class=\"nounderline abstract_t\">Posner S, Colletti L, Knol J, et al. Safety and long-term efficacy of transduodenal excision for tumors of the ampulla of Vater. Surgery 2000; 128:694.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/14\" class=\"nounderline abstract_t\">Yamaguchi K, Enjoji M. Carcinoma of the ampulla of vater. A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer 1987; 59:506.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/15\" class=\"nounderline abstract_t\">Takashima M, Ueki T, Nagai E, et al. Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions. Mod Pathol 2000; 13:1300.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/16\" class=\"nounderline abstract_t\">Standards of Practice Committee, Adler DG, Qureshi W, et al. The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc 2006; 64:849.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/17\" class=\"nounderline abstract_t\">Binmoeller KF, Boaventura S, Ramsperger K, Soehendra N. Endoscopic snare excision of benign adenomas of the papilla of Vater. Gastrointest Endosc 1993; 39:127.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/18\" class=\"nounderline abstract_t\">Desilets DJ, Dy RM, Ku PM, et al. Endoscopic management of tumors of the major duodenal papilla: Refined techniques to improve outcome and avoid complications. Gastrointest Endosc 2001; 54:202.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/19\" class=\"nounderline abstract_t\">Cheng CL, Sherman S, Fogel EL, et al. Endoscopic snare papillectomy for tumors of the duodenal papillae. Gastrointest Endosc 2004; 60:757.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/20\" class=\"nounderline abstract_t\">Hornick JR, Johnston FM, Simon PO, et al. A single-institution review of 157 patients presenting with benign and malignant tumors of the ampulla of Vater: management and outcomes. Surgery 2011; 150:169.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/21\" class=\"nounderline abstract_t\">Shemesh E, Nass S, Czerniak A. Endoscopic sphincterotomy and endoscopic fulguration in the management of adenoma of the papilla of Vater. Surg Gynecol Obstet 1989; 169:445.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/22\" class=\"nounderline abstract_t\">Lambert R, Ponchon T, Chavaillon A, Berger F. Laser treatment of tumors of the papilla of Vater. Endoscopy 1988; 20 Suppl 1:227.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/23\" class=\"nounderline abstract_t\">Ponchon T, Berger F, Chavaillon A, et al. Contribution of endoscopy to diagnosis and treatment of tumors of the ampulla of Vater. Cancer 1989; 64:161.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/24\" class=\"nounderline abstract_t\">Norton ID, Gostout CJ, Baron TH, et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002; 56:239.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/25\" class=\"nounderline abstract_t\">Catalano MF, Linder JD, Chak A, et al. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc 2004; 59:225.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/26\" class=\"nounderline abstract_t\">Han J, Kim MH. Endoscopic papillectomy for adenomas of the major duodenal papilla (with video). Gastrointest Endosc 2006; 63:292.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/27\" class=\"nounderline abstract_t\">Hopper AD, Bourke MJ, Williams SJ, Swan MP. Giant laterally spreading tumors of the papilla: endoscopic features, resection technique, and outcome (with videos). Gastrointest Endosc 2010; 71:967.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/28\" class=\"nounderline abstract_t\">Kim JH, Moon JH, Choi HJ, et al. Endoscopic snare papillectomy by using a balloon catheter for an unexposed ampullary adenoma with intraductal extension (with videos). Gastrointest Endosc 2009; 69:1404.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/29\" class=\"nounderline abstract_t\">Yamao T, Isomoto H, Kohno S, et al. Endoscopic snare papillectomy with biliary and pancreatic stent placement for tumors of the major duodenal papilla. Surg Endosc 2010; 24:119.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/30\" class=\"nounderline abstract_t\">Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60:544.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/31\" class=\"nounderline abstract_t\">Martin JA, Haber GB. Ampullary adenoma: clinical manifestations, diagnosis, and treatment. Gastrointest Endosc Clin N Am 2003; 13:649.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/32\" class=\"nounderline abstract_t\">Bertoni G, Sassatelli R, Nigrisoli E, Bedogni G. Endoscopic snare papillectomy in patients with familial adenomatous polyposis and ampullary adenoma. Endoscopy 1997; 29:685.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/33\" class=\"nounderline abstract_t\">Norton ID, Geller A, Petersen BT, et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001; 96:101.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/34\" class=\"nounderline abstract_t\">Hwang JC, Kim JH, Lim SG, et al. Endoscopic resection of ampullary adenoma after a new insulated plastic pancreatic stent placement: a pilot study. J Gastroenterol Hepatol 2010; 25:1381.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/35\" class=\"nounderline abstract_t\">Rustagi T, Irani S, Reddy DN, et al. Radiofrequency ablation for intraductal extension of ampullary&nbsp;neoplasms. Gastrointest Endosc 2017; 86:170.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/36\" class=\"nounderline abstract_t\">Park SW, Song SY, Chung JB, et al. Endoscopic snare resection for tumors of the ampulla of Vater. Yonsei Med J 2000; 41:213.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/37\" class=\"nounderline abstract_t\">Vogt M, Jakobs R, Benz C, et al. Endoscopic therapy of adenomas of the papilla of Vater. A retrospective analysis with long-term follow-up. Dig Liver Dis 2000; 32:339.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/38\" class=\"nounderline abstract_t\">Charton JP, Deinert K, Schumacher B, Neuhaus H. Endoscopic resection for neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11:245.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/39\" class=\"nounderline abstract_t\">Patel R, Davitte J, Varadarajulu S, Wilcox CM. Endoscopic resection of ampullary adenomas: complications and outcomes. Dig Dis Sci 2011; 56:3235.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/40\" class=\"nounderline abstract_t\">Nguyen N, Shah JN, Binmoeller KF. Outcomes of endoscopic papillectomy in elderly patients with ampullary adenoma or early carcinoma. Endoscopy 2010; 42:975.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/41\" class=\"nounderline abstract_t\">Irani S, Arai A, Ayub K, et al. Papillectomy for ampullary neoplasm: results of a single referral center over a 10-year period. Gastrointest Endosc 2009; 70:923.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/42\" class=\"nounderline abstract_t\">Hoyuela C, Cugat E, Veloso E, Marco C. Treatment options for villous adenoma of the ampulla of Vater. HPB Surg 2000; 11:325.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/43\" class=\"nounderline abstract_t\">Mendon&ccedil;a EQ, Bernardo WM, Moura EG, et al. Endoscopic versus surgical treatment of ampullary adenomas: a systematic review and meta-analysis. Clinics (Sao Paulo) 2016; 71:28.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/44\" class=\"nounderline abstract_t\">Galandiuk S, Hermann RE, Jagelman DG, et al. Villous tumors of the duodenum. Ann Surg 1988; 207:234.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/45\" class=\"nounderline abstract_t\">Cahen DL, Fockens P, de Wit LT, et al. Local resection or pancreaticoduodenectomy for villous adenoma of the ampulla of Vater diagnosed before operation. Br J Surg 1997; 84:948.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/46\" class=\"nounderline abstract_t\">Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg 2010; 14:379.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/47\" class=\"nounderline abstract_t\">Sand JA, Nordback IH. Transduodenal excision of benign adenoma of the papilla of Vater. Eur J Surg 1995; 161:269.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/48\" class=\"nounderline abstract_t\">Alstrup N, Burcharth F, Hauge C, Horn T. Transduodenal excision of tumours of the ampulla of Vater. Eur J Surg 1996; 162:961.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/49\" class=\"nounderline abstract_t\">Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 1997; 225:590.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/50\" class=\"nounderline abstract_t\">Allema JH, Reinders ME, van Gulik TM, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995; 117:247.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/51\" class=\"nounderline abstract_t\">Chareton B, Coiffic J, Landen S, et al. Diagnosis and therapy for ampullary tumors: 63 cases. World J Surg 1996; 20:707.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/52\" class=\"nounderline abstract_t\">Jordan PH Jr, Ayala G, Rosenberg WR, Kinner BM. Treatment of ampullary villous adenomas that may harbor carcinoma. J Gastrointest Surg 2002; 6:770.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/53\" class=\"nounderline abstract_t\">Tran TC, Vitale GC. Ampullary tumors: endoscopic versus operative management. Surg Innov 2004; 11:255.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/54\" class=\"nounderline abstract_t\">Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/55\" class=\"nounderline abstract_t\">Roberts RH, Krige JE, Bornman PC, Terblanche J. Pancreaticoduodenectomy of ampullary carcinoma. Am Surg 1999; 65:1043.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/56\" class=\"nounderline abstract_t\">Sperti C, Pasquali C, Piccoli A, et al. Radical resection for ampullary carcinoma: long-term results. Br J Surg 1994; 81:668.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/57\" class=\"nounderline abstract_t\">Farouk M, Niotis M, Branum GD, et al. Indications for and the technique of local resection of tumors of the papilla of Vater. Arch Surg 1991; 126:650.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/58\" class=\"nounderline abstract_t\">Branum GD, Pappas TN, Meyers WC. The management of tumors of the ampulla of Vater by local resection. Ann Surg 1996; 224:621.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/59\" class=\"nounderline abstract_t\">Gertsch P, Matthews JB, Lerut J, et al. The technique of papilloduodenectomy. Surg Gynecol Obstet 1990; 170:254.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/60\" class=\"nounderline abstract_t\">Beger HG, Staib L, Schoenberg MH. Ampullectomy for adenoma of the papilla and ampulla of Vater. Langenbecks Arch Surg 1998; 383:190.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/61\" class=\"nounderline abstract_t\">Ahn KS, Han HS, Yoon YS, et al. Laparoscopic transduodenal ampullectomy for benign ampullary tumors. J Laparoendosc Adv Surg Tech A 2010; 20:59.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/62\" class=\"nounderline abstract_t\">Huibregtse K, Tytgat GN. Carcinoma of the ampulla of Vater: the endoscopic approach. Endoscopy 1988; 20 Suppl 1:223.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/63\" class=\"nounderline abstract_t\">Seyrig JA, Liguory C, Meduri B, et al. [Endoscopy in tumors of the Oddi region. Diagnostic and therapeutic possibilities]. Gastroenterol Clin Biol 1985; 9:103.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/64\" class=\"nounderline abstract_t\">Huibregtse K, Tytgat GN. Palliative treatment of obstructive jaundice by transpapillary introduction of large bore bile duct endoprosthesis. Gut 1982; 23:371.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/65\" class=\"nounderline abstract_t\">R&ouml;sch W. Endoscopic sphincterotomy in carcinoma of the ampulla of Vater. Gastrointest Endosc 1982; 28:203.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/66\" class=\"nounderline abstract_t\">Vallon AG, Shorvon PJ, Cotton PB. Duodenoscopic sphincterotomy for tumours of the papilla of Vater (abstract). Gut 1982; 23:A456.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/67\" class=\"nounderline abstract_t\">Toussaint J, De Toeuf J, Dunham F, Cremer M. [Periampullary tumors: clinical study and results of palliative or preoperative treatment by endoscopic sphincterotomy (author's transl)]. Acta Gastroenterol Belg 1981; 44:250.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/68\" class=\"nounderline abstract_t\">Alderson D, Lavelle MI, Venables CW. Endoscopic sphincterotomy before pancreaticoduodenectomy for ampullary carcinoma. Br Med J (Clin Res Ed) 1981; 282:1109.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/69\" class=\"nounderline abstract_t\">Valente R, Urban O, Del Chiaro M, et al. ERCP-directed radiofrequency ablation of ampullary adenomas: a knife-sparing alternative in patients unfit for surgery. Endoscopy 2015; 47 Suppl 1 UCTN:E515.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/70\" class=\"nounderline abstract_t\">Mehendiratta V, Desilets DJ. Use of radiofrequency ablation probe for eradication of residual adenoma after ampullectomy. Gastrointest Endosc 2015; 81:1055.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/71\" class=\"nounderline abstract_t\">Bohnacker S, Seitz U, Nguyen D, et al. Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth. Gastrointest Endosc 2005; 62:551.</a></li><li><a href=\"https://www.uptodate.com/contents/ampullary-adenomas-management/abstract/72\" class=\"nounderline abstract_t\">Treitschke F, Beger HG. Local resection of benign periampullary tumors. Ann Oncol 1999; 10 Suppl 4:212.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 649 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2467149757\" id=\"outline-link-H2467149757\">MANAGEMENT</a><ul><li><a href=\"#H654731067\" id=\"outline-link-H654731067\">General approach</a></li><li><a href=\"#H4224614498\" id=\"outline-link-H4224614498\">Selection of a treatment modality</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Endoscopic papillectomy</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">- Endoscopic resection technique</a></li><li><a href=\"#H3181296039\" id=\"outline-link-H3181296039\">- Adjunctive techniques</a></li><li><a href=\"#H2280065766\" id=\"outline-link-H2280065766\">- Prophylaxis for post-ERCP pancreatitis</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Complications</a></li></ul></li><li><a href=\"#H1502852818\" id=\"outline-link-H1502852818\">Surgery</a><ul><li><a href=\"#H85432811\" id=\"outline-link-H85432811\">- Pancreaticoduodenectomy</a></li><li><a href=\"#H4204106490\" id=\"outline-link-H4204106490\">- Surgical ampullectomy</a></li></ul></li><li><a href=\"#H2206746571\" id=\"outline-link-H2206746571\">Endoscopic palliation</a></li></ul></li><li><a href=\"#H1761862354\" id=\"outline-link-H1761862354\">POST-TREATMENT FOLLOW-UP</a><ul><li><a href=\"#H3112295874\" id=\"outline-link-H3112295874\">Incomplete resection and adenoma recurrence</a></li><li><a href=\"#H699284250\" id=\"outline-link-H699284250\">Endoscopic surveillance</a><ul><li><a href=\"#H4267789326\" id=\"outline-link-H4267789326\">- Sporadic adenoma</a><ul><li><a href=\"#H12348341\" id=\"outline-link-H12348341\">Initial surveillance</a></li><li><a href=\"#H1490828151\" id=\"outline-link-H1490828151\">Subsequent surveillance</a></li></ul></li><li><a href=\"#H2668659724\" id=\"outline-link-H2668659724\">- Adenomatous polyposis syndrome</a></li></ul></li></ul></li><li><a href=\"#H24\" id=\"outline-link-H24\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H3306332381\" id=\"outline-link-H3306332381\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/649|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/71691\" class=\"graphic graphic_table\">- Modified Spigelmans score and classification</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=ampullary-adenomas-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Ampullary adenomas: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ampullary-carcinoma-epidemiology-clinical-manifestations-diagnosis-and-staging\" class=\"medical medical_review\">Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscopic-management-of-bile-duct-stones-standard-techniques-and-mechanical-lithotripsy\" class=\"medical medical_review\">Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscopic-removal-of-large-colon-polyps\" class=\"medical medical_review\">Endoscopic removal of large colon polyps</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families\" class=\"medical medical_review\">Familial adenomatous polyposis: Screening and management of patients and families</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-surgery-in-the-treatment-of-exocrine-pancreatic-cancer-and-prognosis\" class=\"medical medical_review\">Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=post-endoscopic-retrograde-cholangiopancreatography-ercp-pancreatitis\" class=\"medical medical_review\">Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prophylactic-pancreatic-stents-to-prevent-ercp-induced-pancreatitis-when-do-you-use-them\" class=\"medical medical_review\">Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-resection-of-lesions-of-the-head-of-the-pancreas\" class=\"medical medical_review\">Surgical resection of lesions of the head of the pancreas</a></li></ul></div></div>","javascript":null}